Bavarian Nordic JYNNEOS is the only U.S. FDA approved non-replicating smallpox and monkeypox vaccine
“Denmark (Precision Vaccinations)
The U.S. Biomedical Advanced Research and Development Authority (BARDA) has exercised the final $12 million option for JYNNEOS, an innovative combination of Smallpox and Monkeypox vaccine.
is the only U.S. Food and Drug Administration-approved non-replicating smallpox and monkeypox vaccine for preventing disease in adults 18 years of age and older.
Initially awarded in April 2020, this option covers the supply of additional liquid-frozen JYNNEOS doses manufactured in Denmark-based Bavarian Nordic A/S’s new fill and finish facility 2021.
The JYNNEOS vaccine is based on a live, attenuated vaccinia virus (Modified Vaccinia Ankara, MVA-BN), incapable of replicating in the body, yet still capable of eliciting a potent immune response.
The MVA is cultured in Chicken Embryo Fibroblast cells placed in a serum-free medium. It is purified and filtered from the cells using various methods, including benzonase digestion.”